# Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09

> **NCT04354090** · PHASE1 · COMPLETED · sponsor: **Beijing Dongfang Biotech Co., Ltd.** · enrollment: 41 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** JY09

## Key facts

- **NCT ID:** NCT04354090
- **Lead sponsor:** Beijing Dongfang Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-26
- **Primary completion:** 2018-12-27
- **Final completion:** 2019-06-22
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04354090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04354090, "Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04354090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*